As a link between basic and clinical science, the breast Cancer translational research Laboratory aims to accelerate our ability to translate findings made in basic research into real applications at the patient’s bedside. PrOF CHriStOS SOtiriOu, Head of the breast Cancer translational research Laboratory Jean-Claude Heuson

current research activities Genetic and epigenetic characterisation of breast cancer and its associated stroma using the next generation of sequencing tools.

Role of tumour microenvironment in breast cancer development and progression. This research, using molecular biology to establish prognostic signatures, contributes to a better understanding of the mechanisms that trigger the progression of tumours according to different molecular subgroups.

Molecular characterisation of CTCs and DTCs. This research is being conducted to understand the metastatic progression of breast cancer as well as to refine prognosis (natural evolution of the disease) and prediction (response to therapy) in early breast cancer. So far, the molecular detection of peripheral CK19mRNA-positive cells in the blood has been shown to be an independent prognostic factor for poor outcome in women with early breast cancer.

Analysis of functional signalling output associated with major genetic aberrations in breast cancer. The Laboratory is also centrally involved in prospective clinical trials that aim to evaluate predictive markers. In one such study, new molecular markers have been identified to predict response and resistance to anthracyclines, one of the most commonly administered classes of chemotherapeutic drugs.